Novo Indonesia Strategy Encourages Public Active Role in Ensuring Medication Safety
Jakarta, VIVA – Global pharmaceutical manufacturer, Novo, has reaffirmed its commitment to supporting patient safety through the management of product quality and security at every stage of treatment.
Dr Riyanny Meisha Tarlinan, Associate Director of Medical & Regulatory at Novo Indonesia, stated that in the spirit of World Patient Safety Day 2026, this is crucial because patient safety is not only determined by the quality of healthcare services, but also by the safety of the medications used during the treatment stages.
She explained that for individuals living with non-communicable diseases (NCDs) such as diabetes and obesity, treatment can be long-term and requires continuous monitoring. Consequently, Novo Indonesia is committed to placing patient safety as its top priority, manifested by maintaining quality and safety aspects from product manufacturing to patient use.
“Through collaboration and the active role of every party, we can together support a safer treatment journey for patients,” she said.
“For Novo, these efforts begin with the implementation of processes and quality standards before products are marketed, systems to ensure product authenticity, efforts to support the detection of illegal products, and monitoring safety after product use through Pharmacovigilance responsibilities,” said Riyanny.
The public can also play an active role in maintaining treatment safety, one way being by ensuring that prescription medications are obtained through official channels, verifying product legality, and using them according to instructions from healthcare professionals.
As options for the public to obtain health products become increasingly diverse, ensuring the validity and source of medication becomes a vital part of maintaining treatment safety.
“Therefore, public understanding of what constitutes illegal products and the risks they may pose is an essential part of maintaining treatment safety,” she added.
It is noted that the World Health Organisation (WHO) explains that substandard and falsified medical products may contain harmful substances or incorrect dosages. As a result, their efficacy, safety, and quality are not guaranteed. Such conditions can lead to treatment failure, worsen health conditions, and even pose a risk of death.
Source: jawawa.id (https://jawawa.id/newsitem/novo-indonesia-strategy-encourages-public-active-role-in-ensuring-medication-safety-1789661650)
Originally published by VIVA.co.id (https://www.viva.co.id/bisnis/1929333-strategi-novo-indonesia-dorong-masyarakat-berperan-aktif-memastikan-keamanan-penggunaan-obat), translated from Indonesian